Ayala Pharmaceuticals has been granted a patent for recombinant fusion polypeptides containing antigenic peptides from cancer-associated proteins, including recurrent and heteroclitic mutations. The patent covers methods of inducing anti-tumor immune responses, treating cancer, and developing vaccines using these fusion polypeptides. GlobalData’s report on Ayala Pharmaceuticals gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Ayala Pharmaceuticals Inc. - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Ayala Pharmaceuticals, Personalized cancer vaccines was a key innovation area identified from patents. Ayala Pharmaceuticals's grant share as of February 2024 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Recombinant fusion polypeptides for cancer immunotherapy

Source: United States Patent and Trademark Office (USPTO). Credit: Ayala Pharmaceuticals Inc.

A recently granted patent (Publication Number: US11897927B2) discloses a novel recombinant Listeria strain designed to induce an immune response against cancer. The strain contains a nucleic acid encoding a fusion polypeptide with a PEST-containing peptide fused to two or more antigenic peptides, including those from cancer-associated proteins with recurrent or heteroclitic mutations. The fusion polypeptide also includes a ubiquitin protein and a carboxy-terminal antigenic peptide, arranged in tandem from the amino-terminal end to the carboxy-terminal end. The antigenic peptides encompass mutations from various cancer-related genes, such as SPOP, CHEK2, RGPD8, ANKRD36C, and AR, or heteroclitic mutations from genes like CEACAM5, MAGEA4, and STEAP1.

Furthermore, the patent claims cover various aspects of the recombinant Listeria strain, including the specific mutations present in the antigenic peptides, the length and composition of the peptides, the use of peptide linkers, and the molecular weight of the fusion polypeptide. The patent also extends to immunogenic compositions comprising the recombinant Listeria strain, methods of inducing an immune response against cancer in a subject using the strain, and the creation of a cell bank containing the recombinant Listeria strains. The innovative approach outlined in the patent aims to leverage the unique properties of Listeria to target cancer-specific mutations and enhance the body's immune response against tumors.

To know more about GlobalData’s detailed insights on Ayala Pharmaceuticals, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies